Modification of tumour blood flow using the hypertensive agent, angiotensin II
1993

Modification of Tumour Blood Flow Using Angiotensin II

Sample size: 29 publication Evidence: moderate

Author Information

Author(s): G.M. Tozer, K.M. Shaffi

Primary Institution: CRC Gray Laboratory

Hypothesis

Can angiotensin II modify blood flow in tumours and normal tissues?

Conclusion

Angiotensin II infusion reduces blood flow to the P22 tumour while increasing vascular resistance.

Supporting Evidence

  • Angiotensin II increased mean arterial blood pressure significantly.
  • Blood flow to the tumour was reduced to about 80% of control values.
  • Vascular resistance increased significantly in all tissues studied.

Takeaway

This study looked at how a drug called angiotensin II affects blood flow in tumours. It found that while it can change blood flow, it actually reduces the blood flow to the tumour itself.

Methodology

The study measured blood flow and vascular resistance in BD9 rats using angiotensin II at various doses.

Potential Biases

Potential bias due to inter-transplant variation in blood flow.

Limitations

The study was limited to a specific tumour type and may not generalize to all tumours.

Participant Demographics

Male BD9 rats aged 10 to 12 weeks.

Statistical Information

P-Value

0.01

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication